Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorElfiky, Abdo A.-
Data de aceite: dc.date.accessioned2026-02-09T12:36:07Z-
Data de disponibilização: dc.date.available2026-02-09T12:36:07Z-
Data de envio: dc.date.issued2020-05-19-
Data de envio: dc.date.issued2020-05-19-
Data de envio: dc.date.issued2020-05-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41078-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0024320520302253-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1164575-
Descrição: dc.descriptionAims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). Materials and methods In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. Significance The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceLife Sciences-
Palavras-chave: dc.subjectWuhan coronavirus-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectRNA dependent RNA polymerase (RdRp)-
Palavras-chave: dc.subjectDocking-
Palavras-chave: dc.subjectStructural bioinformatics-
Palavras-chave: dc.subjectSofosbuvir-
Palavras-chave: dc.subjectNucleotide inhibitors-
Título: dc.titleAnti-HCV, nucleotide inhibitors, repurposing against COVID-19-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.